4.8 Article

Androgen insensitivity syndrome

期刊

LANCET
卷 380, 期 9851, 页码 1419-1428

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(12)60071-3

关键词

-

资金

  1. Pfizer
  2. Novo Nordisk
  3. Ferring
  4. Merck Serono
  5. Ipsen
  6. Newlife
  7. EC within EuroDSD [201444]
  8. Medical Research Council [G1100236] Funding Source: researchfish
  9. MRC [G1100236] Funding Source: UKRI

向作者/读者索取更多资源

Androgen insensitivity syndrome in its complete form is a disorder of hormone resistance characterised by a female phenotype in an individual with an XY karyotype and testes producing age-appropriate normal concentrations of androgens. Pathogenesis is the result of mutations in the X-linked androgen receptor gene, which encodes for the ligand-activated androgen receptor-a transcription factor and member of the nuclear receptor superfamily. This Seminar describes the clinical manifestations of androgen insensitivity syndrome from infancy to adulthood, reviews the mechanism of androgen action, and shows examples of how mutations of the androgen receptor gene cause the syndrome. Management of androgen insensitivity syndrome should be undertaken by a multidisciplinary team and include gonadectomy to avoid gonad tumours in later life, appropriate sex-hormone replacement at puberty and beyond, and an emphasis on openness in disclosure.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据